Gene Panel for detecting multiple tumors, kit and application

Abstract

The invention discloses a gene Panel for detecting various tumors, a kit and application. The gene Panel comprises a genetic breast cancer and ovarian cancer syndrome BRCA related gene, a Lingchi syndrome related gene, other genes related to the plurality of tumors and a homologous recombination repair pathway key gene. The kit can be used for detecting the level of an embryonic system or a combined tumor tissue level aiming at genetic breast cancer and ovarian cancer syndrome BRCA related genes, Lingchi syndrome related genes, other genes related to various tumors and homologous recombination repair pathway key genes; the genetic risks of the genes related to gynecological tumors, breast cancers, prostatic cancers and digestive tract tumors are accurately evaluated according to detection results, and the application conditions of platinum chemotherapeutic drugs and PARP inhibitors related to tumor patients are guided. And comprehensive guidance for precise treatment of various tumors such as gynecological tumors, breast cancers, prostatic cancers and digestive tract tumors is realized through one-time detection.

Description

technical field [0001] The invention relates to the technical field of tumor multi-gene detection, in particular to a gene panel, a kit and an application for detecting multiple tumors. Background technique [0002] According to statistics, the morbidity and mortality of gynecological tumors, breast cancer, prostate cancer and digestive tract tumors are very high. Clinical studies classify tumors as a genetic disease, which is mainly caused by the activation of proto-oncogenes or the inactivation of inhibitory genes. With the great progress of high-throughput sequencing (NGS) and biotechnology, multiple driver genes related to the occurrence and development of cancer and biomarkers that can be used to guide tumor treatment have been discovered, and a number of driver genes and biomarkers have been developed. In clinical treatment, precise treatment can be carried out based on detected driver gene mutations or biomarkers. Therefore, the detection of tumor-related driver gen...

AI Technical Summary

Problems solved by technology

Among them, although Sanger sequencing is the gold standard for sequencing, because the sequencing technology can only obtain one sequence in one reaction, the sequencing throughput is low; although the price of a single reaction is low, the cost of obtaining a large number of sequencing is high; the detection sensitivity is low, generally Only mutations with a mutation abundance above 20% can be detected, and some low-frequency mutations may be missed

RT-PCR can only detect known sites and cannot discover unknown sites

IHC is mainly used to detect protein expression, and cannot detect gene point mutations (SNV), small fragment insertion-deletion (Indel), etc. Therefore, the detection of medication that needs to be guided by gene SNV / Indel cannot be achieved by IHC

Although FISH detection is the gold standard for identifying gene fusion (Fusion) and amplification (CNV), it is also not applicable to the detection of SNV / Indel

However, there is currently no high-throughput sequencing technology that can simultaneously detect multiple tumors such as gynecological tumors, breast cancer, prostate cancer, and digestive tract tumors

Images